검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chemotherapy of Physician's Choice (Chemotherapy of Physician's Choice) Sichuan Baili Pharmaceutical Co., …·HER2 ORR 100% |
|---|---|
Overview Program | Chemotherapy of Physician's Choice |
Overview Company | Sichuan Baili Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | HER2-positive |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.. We performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribuli… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT02000622 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Chemotherapy of Physician's Choice (Chemotherapy of Physician's Choice) Sichuan Baili Pharmaceutical Co., …·HER2 ORR 100% |
|---|---|
Overview Program | Chemotherapy of Physician's Choice |
Overview Company | Sichuan Baili Pharmaceutical Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | HER2 |
Overview Indication | HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | HER2-positive |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.. We performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribuli… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT02000622 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교